PRESS RELEASE: CTAC calls for unlimited access to breakthrough hepatitis C drugs
july 21, 2015
JULY 21, TORONTO - Current restrictions on Hepatitis C drugs could negatively impact the health of more than 300,000 Canadians infected with Hepatitis C. Public formularies that have listed drugs like Harvoni currently limit their use to patients with advanced liver cirrhosis(stage F2). Due to the infectiousness of the hepatitis C virus (HCV), a delay in Hepatitis C treatment could risk increasing the number of infections we see annually. Delayed treatment is also known to decrease the recovery success of those infected with the virus.
“The F2 criteria for HCV treatment should be revised. With the advent of new, less demanding medications, treating HCV before symptoms begin is the best approach,” says Shane Patey, Executive Director of the Canadian Treatment Action Council (CTAC). “A delay in treatment for those living with Hepatitis C is not only a social injustice; it is also a public health risk.”